Inflammation, impaired motor function and visceral hypersensitivity: the main mechanisms of functional disorders of the gastrointestinal tract (materials of the Expert Council and literature review)

Aim. To review the main mechanisms of functional disorders of the gastrointestinal tract and to present the materials of an Expert Council, which was held on 10 December 2021 in Moscow.

Key points. The pathogenesis of the most common functional diseases of the gastrointestinal tract — functional dyspepsia (FD) and irritable bowel syndrome (IBS) is multifactorial and includes motor disorders of various parts of the gastrointestinal tract, visceral hypersensitivity, changes in the intestinal microbiome, impairment of the permeability of the protective barrier, low-grade inflammation of the gastrointestinal mucosa, etc. This often leads to the prescription of a complex of various medications to such patients, which increases the risk of undesirable drug interactions and side effects. Multitargeted therapy involves the use of drugs that simultaneously affect different pathogenetic links. One of these drugs is Iberogast®, which normalizes gastrointestinal motility and visceral sensitivity, has an anti-inflammatory action and is highly effective in treatment of FD and IBS.

Conclusion. In the treatment of functional gastrointestinal diseases characterized by multifactorial pathogenesis, preference should be given to multi-targeted therapy with the use of drugs that have an effect on its various links.

1. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M., et al. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Rus J Gastroenterol Hepatol Coloproctology. 2017;27(1):50–61 (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-50-61

2. Ivashkin V.T., Shelygin Yu.A., Baranskaya Y.K., Belousova Y.A., Beniashvili A.G., Vasilyev S.V., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(5):76–93 (In Russ.). DOI: 10.22416/1382-4376-2017-27-5-76-93

3. Drossman D.A. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016:S0016-5085(16)00223-7. DOI: 10.1053/j.gastro.2016.02.032

4. Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N Engl J Med. 2017;376(26):2566–78. DOI: 10.1056/NEJMra1607547

5. Black C.J. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396(10263):1664–74. DOI: 10.1016/S0140-6736(20)32115-2

6. Allescher H.-D., Burgell R., Malfertheiner P., Mearin F. Multi-target treatment for irritable bowel syndrome with STW 5: pharmacological modes of action. J Gastrointestin Liver Dis. 2020;29(2):227–33. DOI: 10.15403/jgld-814

7. Stanghellini V., Chan F.K.L., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., Talley N.J. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92. DOI: 10.1053/j.gastro.2016.02.011

8. Sheptulin A.A., Storonova O.A., Rumyantseva D.E. Consensus Meeting of European Society of Neurogastroenterology and Motility on functional dyspepsia (2020): have we dotted all the i’s? Rus J Gastroenterol Hepatol Coloproctology. 2021;31(2):40–5 (In Russ.). DOI: 10.22416/1382-4376-2021-31-2-40-45

9. Ivashkin V.T., Sheptulin A.A., Kiprianis V.A. Functional dyspepsia. Moscow: MEDpress-inform, 2017. 144 p. (In Russ.).

10. Von Arnim U., Peitz U., Vinson B., Gundermann K.-J., Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102(6):1268–75. DOI: 10.1111/j.1572-0241.2006.01183.x

11. Melzer J., Rösch W., Reichling J., Brignoli R., Saller R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther. 2004;20(11–12):1279–87. DOI: 10.1111/j.1365-2036.2004.02275.x

12. Ford A.C., Marwaha A., Sood R., Moayyedi P. Global prevalence of, and risk factors for uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64(7):1049–57. DOI: 10.1136/gutjnl-2014-307843

13. Wauters L., Dickman R., Drug V., Mulak A., Serra J., Enck P., Tack J. and the ESNM FD consensus group. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. United European Gastroenterol J. 2021;9(3):307–31. DOI: 10.1002/ueg2.12061

14. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67. DOI: 10.1136/gutjnl-2015-309252

15. Moayyedi P ., Soo S., Deeks J., Delaney B., Harris A., Innes M., et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;2:CD002096. DOI: 10.1002/14651858.CD002096.pub4

16. Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016:S0016-5085(16)00222-5. DOI: 10.1053/j.gastro.2016.02.031

17. Ford A.C., Mahadeva S., Carbone M.F., Lacy B.E., Talley N.J. Functional dyspepsia. Lancet. 2020;396(10263):1689–702. DOI: 10.1016/S0140-6736(20)30469-4

18. Ivashkin V.T., Poluektova E.A., Reykhart D.V., Shifrin O.S., Beniashvili A.G., Lyashenko O.S., Belostotsky A.V. Efficacy of drugs most commonly prescribed at functional gastrointestinal diseases (functional dyspepsia syndrome and irritable bowel syndrome) observational study results. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(4):14–23 (In Russ.). DOI: 10.22416/1382-4376-2016-26-4-14-23

19. Geeraerts A., Van Houtte B., Clevers E., Geysen H., Vanuytsel T., Tack J., Pauwels A. Gastroesophageal Reflux Disease-Functional Dyspepsia Overlap: Do Birds of a Feather Flock Together? Am J Gastroenterol. 2020;115(8):1167–82. DOI: 10.14309/ajg.0000000000000619

20. Petrini E, Caviglia G.P., Pellicano R,. Saracco G.M., Morino M., Ribaldone D.G. Risk of drug interactions and prescription appropriateness in elderly patients. Ir J Med Sci. 2020;189(3):953–9. DOI: 10.1007/s11845-019-02148-8

21. Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G.E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. DOI: 10.1186/s12877-017-0621

22. Mortazavi S.S., Shati M., Keshtkar A., Malakouti S.K., Bazargan M., Assari S. Defining polypharmacy in the elderly: a systematic review protocol. BMJ Open. 2016;6(3):e010989. DOI: 10.1136/bmjopen-2015-010989

23. Sychev D.A., Otdelеnov V.A., Krasnova N.M., Ilyina E.S. Polypragmasy: A clinical pharmacologist’s view. Terapevticheskii arkhiv. 2016;88(12):94–102 (In Russ.). DOI: 10.17116/terarkh2016881294-102

24. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Sheptulin A.A., Simanenkov V.I., Lapina T.L., et al. Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week). Rus J Gastroenterol Hepatol Coloproctol. 2020;30(6):7–18 (In Russ.). DOI: 10.22416/1382-4376-2020-30-6-7-18

25. Simanenkov V.I., Maev I.V., Tkacheva O.N., Alekseenko S.A., Andreev D.N., Bordin D.S., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (In Russ.). DOI: 10.15829/1728-8800-2021-2758

26. Malfertheiner P. STW5 (Iberogast®) therapy in gastrointestinal functional disorders. Dig Dis. 2017;35(suppl. 1):25–9. DOI: 10.1159/000485410

27. Hohenester B., Rühl A., Kelber O., Schemann M. The herbal preparation STW5 (Iberogast®) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil. 2004;16(6):765–73. DOI: 10.1111/j.1365-2982.2004.00648.x

28. Pilichiewicz A.N., Horowitz M., Russo A., Maddox A., Jones K.L., Schemann M., et al. Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Amer J Gastroenterol. 2007;102(6):1276–83. DOI: 10.1111/j.1572-0241.2007.01142.x

29. Simmen U., Kelber O., Okpanyi S.N., Jaeggi R., Bueter B., Weiser D. Bimding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine. 2006;13(suppl. 5):51–5. DOI: 10.1016/j.phymed.2006.03.012

30. Liu C.-Y., Müller M.H., Glatzle J., Weiser D., Kelber O., Enck P., et al. The herbal preparation STW5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil. 2004;16(6):759–64. DOI: 10.1111/j.1365-2982-2004.00576.x

31. Khalil M., Zhang Z., Abdel-Aziz H., Rabini S., Ammar R.M., Reeh P.W., et al. Dual opposing actions of STW5 on TRP receptors mediate neuronal desensitization in vitro. Life Sci 2020;257:118112. DOI: 19.1016/j.lfs.2020.118112

32. Michael S., Kelber O., Нauschildt S., Spanel-Borowski K., Nieber K. Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW5 and STW6. Phytomedicine 2009;16:161–71. DOI: 10.1016/j.phymed.2008.10.011

33. Wadie W., Abdel-Aziz H., Zaki H.F., Kelber O., Weiser D., Khayyal T. STW5 is effective in dextran sulfate sodium-induced colitis in rats. Int J Colorectal Dis. 2012;27(11):1445–53. DOI: 10.1007/s00384-012-1473-z

34. Elbadawi M., Ammar R.M., Aziz-Kalbhenn H., Rabini S., Klauck S.M., Dawood M., et al. Anti-inflammatory and tight junction protective activity of the herbal preparation STW 5-II on mouse intestinal organoids. Phytomedicine 2021;88:153589. DOI: 10.1016/j.phy-med.2021.153589

35. Khayyal M.T., El-Ghazaly M.A., Kenawy S. Seif-El-Nasr M., Mahran L.G., Fafafi Y.A., et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneim Forsch Drug Res. 2001;51(7):545–53. DOI: 10.1055/s-0031-1300078

36. Allescher H.D., Wagner H. STW5/Iberogast®: Multi-Target Wirkung bei funktioneller Dyspepsie und Reizdarmsyndrom. Wien Med Wochenschr. 2007;157:301–7.